Longevity Health Holdings Soars 82.68% on Nasdaq Approval

Longevity Health Holdings, Inc. has seen a remarkable surge in its stock price, rising by 82.68% in pre-market trading on May 22, 2025. This significant increase comes on the heels of several strategic developments that have bolstered investor confidence in the company's future prospects.

One of the key drivers behind this surge is the company's recent approval from the Nasdaq Hearings Panel to continue its listing on the Nasdaq. This approval is contingent on Longevity Health meeting initial listing requirements following its proposed merger with 20/20 Biolabs by September 2, 2025. The decision reflects the company's strategic plan, which includes a 1-for-30 reverse stock split and the filing of an S-4 registration statement for the merger. These steps are aimed at ensuring compliance with Nasdaq's rules and advancing the company's mission in the longevity solutions market.

Longevity Health Holdings is focused on extending human longevity and healthy aging through innovative products in regenerative bio-aesthetics, diagnostics, and nutrition. The company offers technologies for skin and hair health, including Carmell Secretome and Elevai Exosomes. These products are at the forefront of the company's efforts to provide cutting-edge solutions in the longevity market, which has garnered significant interest from investors.

The company's shares surged in extended trading following the Nasdaq approval, reflecting the market's positive response to these developments. The strategic moves by Longevity Health, including the reverse stock split and the merger with 20/20 Biolabs, are seen as crucial steps in strengthening the company's financial position and market standing. As the company continues to execute its strategic plan, investors are closely watching for further developments that could impact its stock price.